Audacity MD

INFJ; Physician-Scientist; Plant dad 🌱

[Dr Gordon Caldwell @doctorcaldwell]

Having read the @gmcuk Outcomes for Graduates of Medical Schools, I suggest all UK Medical Students sit USA exams, USMLE. There's a serious danger UK Medical Qualifications might not be recognised outside UK - so little emphasis on Medical Knowledge & Expertise. @DrLKVaughan

[Sonny @rawespresso]

Sit on any UK commuter train at 7:43am on a Monday and you'll see something that should be more uncomfortable than it is.

A carriage of adults in their thirties and forties, standing up shoulder to shoulder, headphones in, eyes locked on the floor or their phones, completely silent. Some of them have been doing this exact journey for 6, 8, 12 years.

Nobody is talking, nobody is making eye contact, and everyone has already rehearsed the next 12 hours in their head before the train has even left the station.

This is what the country quietly calls 'a good job in the city.'

[Audacity MD @zee_cv]

Nothing truly great or worthwhile has ever been achieved without enthusiasm.

[Audacity MD @zee_cv]

Can’t even remember the last time I touched cash

[katie from hell౨ৎ @ilyiskatie]

wait ppl actually rely only on apple pay and don't bring their physical cards with them🧍🏼‍♀️

[NEJM @NEJM]

HLA sensitization poses major challenges to kidney transplantation. A new report describes transplantation in two highly sensitized candidates after desensitization with dual CAR T-cell therapy. Read the full report: https://t.co/9t9TMQJkK2

Correspondence: Kidney Transplantation after Clearing Anti-HLA Antibodies with CD19 CAR T Cells https://t.co/S8zRj9E4vi

[NEJM @NEJM]

In an African study of severe malaria in children with partially artemisinin-resistant parasites with PfK13 mutations, artesunate did not lead to worse outcomes, which suggests that parenteral artesunate may still be used. Full SMAART-CHARISMA study results: https://t.co/ckeM7otwCJ

[Allison Fitzgerald, MD, PhD @allisonoconn]

If your main criticism of a new cancer drug that doubles overall survival is “it’s not a cure”, please work on developing intellectually rigorous clinical trial assessments.

And while we’re at it, how about some empathy? An extra YEAR of life is nothing to balk at

[Mauro Lago-Docampo @MuruLago]

I still think MDPI journals can have legit papers every now and then, but they are totally buried in a mountain of low-quality papers and terrible reviews.

Long story short, I avoid citing MDPI stuff in general because they ignore reviewers.

[Mauro Lago-Docampo @MuruLago]

In January, I reviewed a Review for a crappy MDPI journal.

It was 100% AI, missing citations, etc. I sent a massive report, and the authors withdrew it.

Today, I see it published without a single change in another even crappier MDPI journal.

[JAMA Network Open @JAMANetworkOpen]

Immigrants from banned countries contributed nearly 24 000 physicians and 56 000 nurses to the US workforce in 2023, with higher presence in counties with workforce shortages and vulnerable populations.

#ARM26 @AcademyHealth

https://t.co/l93CoUXlkX

[Ethan J. Weiss @ethanjweiss]

As a non-oncologist, i feel quite comfortable jumping on the bandwagon here. I can count the number of times I've seen unsolvable problems in medicine get solved in my lifetime. No, this is not a cure, but there has been no greater challenge than pancreatic cancer. Nothing worked. Now this...

These results are simply spectacular

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | New England Journal of Medicine https://t.co/a52WwDQ2Ju

[NEJM @NEJM]

Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) https://t.co/y4G27hfORg

#ASCO26 | @ASCO

[Keith Siau @drkeithsiau]

An INCREDIBLE advance in pancreatic cancer. Compared to conventional treatment, Daraxonrasib, a new RAS inhibitor, was shown to increase survival in metastatic pancreatic cancer in this landmark NEJM trial:

> Median survival doubled
> 12-month survival tripled (18% to 53%)
> Less discontinuation (1.2% vs 11.2%)

Pancreatic cancer carries one of the worst prognosis - most cases carry a KRAS mutation which is targeted by this new class of treatment, bringing much needed hope to patients with this cancer, and potentially affecting other sites 🤞👏

https://t.co/bqHKoh1qS3

[Parmita Mishra @parmita]

RAS finally getting drugged is one of the great stories in modern biology, and almost nobody outside oncology understands why it's such a big deal.

YOU'LL LEARN SOMETHING AWESOME TODAY.

i am going to keep this as understandable (and simple) as i can.

OPEN THE THREAD.

🧵

[Blonde of War (JJ) @BlondeOfWar]

Necessity is the mother of invention, or maybe the father in this case. 😂🥰

[nature @Nature]

Nature research paper: Universal transcriptomic hallmarks of mammalian ageing and mortality

https://t.co/9IbuF2tK5H

[nature @Nature]

The US National Science Foundation (NSF) — a major funder of basic research — has restricted the flow of new research grants to a group of elite universities, Nature has learnt.

https://t.co/dUcCrJh4Dm

[Audacity MD @zee_cv]

@mxxyx22 @Oluwatobby_ 😂😂

[Ajibola @4jibola]

the desire to become better can literally consume you

[Reads with Ravi @readswithravi]

Kaizen - A Japanese concept of continuous improvement.